gvs 111 has been researched along with Brain Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Neznamov, GG; Teleshova, ES | 2 |
| Gudasheva, TA; Kamenskiĭ, AA; Nazarenko, IV; Volkov, AV | 1 |
3 other study(ies) available for gvs 111 and Brain Diseases
| Article | Year |
|---|---|
[A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin].
Topics: Adolescent; Adult; Brain Diseases; Brain Injuries; Cognition Disorders; Dipeptides; Humans; Middle Aged; Neuroprotective Agents; Nootropic Agents; Piracetam; Time Factors; Treatment Outcome | 2008 |
Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin.
Topics: Adolescent; Adult; Brain Diseases; Brain Injuries; Cognition Disorders; Dipeptides; Humans; Middle Aged; Neuroprotective Agents; Nootropic Agents; Piracetam; Time Factors; Treatment Outcome | 2009 |
[Postresuscitation restoration of central nervous system functions during systemic administration of new peptide analog of pyracetam].
Topics: Animals; Brain; Brain Diseases; Cardiopulmonary Resuscitation; Constriction; Coronary Vessels; Dipeptides; Exploratory Behavior; Male; Motor Activity; Nootropic Agents; Orientation; Rats | 1998 |